The global immunoglobulin market size was estimated to be US$ 12.5 billion in 2021 and is expected grow at a CAGR of 7% between 2023 to 2032. Immunoglobulins are characterized as a type of glycoprotein molecules that are produced by white blood cells (WBCs) or plasma. They are also known as antibodies that identify antigens such as bacteria and viruses by binding to them and also neutralizing them. In many people, immunoglobulins need to be administered via different routes for the body to neutralize pathogens and to maintain immunity.
The property of Immunoglobulins to correctly identify and bind to antigens also helps in diagnosis of multiple diseases such as immune deficiencies, allergies and auto immune diseases namely celiac disease, lupus and arthritis. Based on biological structure, target specificity, distribution and characteristics different immunoglobulins are classified accordingly.
There is a great demand for immunoglobulins for treatment and diagnostic purposes due to increased awareness and greater efficiency. Its proven efficiency in treating rare immunodeficiency disorders like chronic inflammatory demyelinating polyneuropathy (CIDP) is bolstering the market growth.
Global Immunoglobulin market dynamics
Rise in the incidences of autoimmune and chronic diseases
The rising number of patients suffering from autoimmune diseases such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will drive market growth
Increase in geriatric population
In many developed countries the population of people over 60 years in steadily increasing. As the persons age increases the incidences of autoimmune and chronic diseases also increase.
Rise in the prevalence of sedentary lifestyle
As more and more people are consuming fast foods as a result of increased urbanization, stressful and sedentary lifestyles this market is predicted to grow.
Increase in the number of research and development activities
The number of research and development activities for autoimmune disorders has increased and there is an increase in investment for developing new and advanced technologies that will bolster this market growth during the forecast period.
COVID-19 impact on global market
The global pandemic of COVID-19 has offered pharmaceutical companies numerous opportunities to increase their research and development budgets in order to offer treatment options to critically ill COVID-19 patients. Immunoglobulin therapy for COVID-19 infection has shown to be favorable in treating COVID-19. Also, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.
Challenges in the globalImmunoglobulin market
High costs in manufacturing
Developing immunoglobulins is a highly complex and costly process that requires significant investments, clinical trial expertise, quality systems, scientific standards and technical capabilities. Immunoglobulin manufacturers are required to invest in clinical trials and post-approval safety monitoring programs due to stringent regulations required by the regulators.
Lack of skilled professionals
There is a shortage of skilled healthcare professionals and also lack of training to administer immunoglobulin therapies. Also, there are few apprehensions about the safety of this therapy among the healthcare community. Therefore, the lack of awareness and skills could be restraining factors for market growth.
Immunoglobulin Market Share Analysis, by Geography (2021)
The major players operating in the immunoglobulins market are Baxter, Biotest AG, China Biologic Products Holdings Inc, CSL Limited, Grifols S.A., Kedrion S.p.A, Octapharma, GREEN CROSS CORP, Coram LLC, Momenta Pharmaceuticals, Option Care Enterprises Inc, ADMA Biologics Inc, Gentian Diagnostics AS, Mabtech, Mitra & Co. Pvt. Ltd, Cygnus Technologies, Kamada Pharmaceuticals, HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD, Kedrion Biopharma Inc, Hualan Biological Engineering Inc and others.
Market Segmentation as below:
Chronic Inflammatory Demyelinating Polyneuropathy
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura
Specific Antibody Deficiency
By Mode of Delivery
Rest of North America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of the Middle East & Africa
Rest of South America
InsightSLICE adopts a research methodology which is highly meticulous and comprehensive, yielding accurate research results. Our research methodology utilizes data triangulation model which helps in the precise collection and validation of information. Our set processes for problem solving and paid primary tools guarantee that any client requirement is met with utmost diligence and accuracy. Some of the primary components that are consequential to our research approach are:
Secondary Research or Desk Research
Distinctive Data Model
Secondary Sources include but are not limited to:
Past Published Research
Historical Data and Information
Primary Sources include but are not limited to:
InsightSLICE also leverages three types of data triangulation approaches as follows:
Data Source Triangulation
Extracting data and validation from multiple type of secondary and primary sources
Combining various methodologies to validate data inputs
Applying different theories to check credibility of data sets